Well Referenced

Tag: Radical Prostatectomy

Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial

The ProtecT trial is a randomized controlled trial that compared active monitoring, radical prostatectomy, and radiotherapy for men with localized prostate cancer. It involved 1,643 participants and aimed to provide contemporary data on the outcomes of these treatment options. The study found no significant difference in prostate cancer-specific mortality between

Read More »
June 26, 2025 No Comments

External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores

A study published in Cancer Journal for Scientists and Clinicians (1997) compared the efficacy of external beam radiotherapy (RT) and radical prostatectomy (RP) for treating clinical stage T1-2 prostate cancer. The study included 551 patients and found that RP led to a 57% 5-year biochemical relapse-free survival rate, while RT

Read More »
June 26, 2025 No Comments

Long-term quality of life in prostate cancer

The commentary discusses the long-term quality of life outcomes in prostate cancer patients, referencing the Prostate Cancer Outcomes Study (PCOS), which followed 1,655 men aged 55-74 years over 15 years. The study found significant declines in sexual, urinary, and bowel function across all treatment modalities. Erectile dysfunction was prevalent in

Read More »
June 26, 2025 No Comments

Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial

This randomized controlled trial examined long-term quality-of-life outcomes in 400 Swedish and Finnish men with localized prostate cancer randomized to either radical prostatectomy or watchful waiting, with a median follow-up of 12.2 years. Self-assessed high quality of life was reported by 35% in the prostatectomy group, 34% in the watchful

Read More »
June 26, 2025 No Comments

Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow

This review article examines the management of localized prostate cancer, highlighting watchful waiting, radical prostatectomy, and radiation therapy as primary treatment options. It emphasizes that prostate cancer often progresses slowly, particularly in men over 65, making active surveillance a viable option for many patients. The choice of treatment should be

Read More »
June 26, 2025 No Comments

Prostate cancer–uncertainty and a way forward

This editorial discusses the findings of a study comparing radical prostatectomy to observation in men with localized prostate cancer, emphasizing the uncertainty in determining the optimal management strategy. The study found no significant difference in all-cause mortality between men undergoing surgery and those under observation, though surgery reduced disease-specific mortality

Read More »
June 26, 2025 No Comments

Radical prostatectomy versus observation for localized prostate cancer

This randomized controlled trial compared radical prostatectomy with observation in 731 men with clinically localized prostate cancer over a median follow-up of 10 years. The study found no significant reduction in all-cause mortality (47.0% vs. 49.9%; HR 0.88; 95% CI, 0.71–1.08; P=0.22) or prostate-cancer-specific mortality (5.8% vs. 8.4%; HR 0.63;

Read More »
June 26, 2025 No Comments

The role of testosterone replacement therapy following radical prostatectomy

This review examined the potential role of testosterone replacement therapy (TRT) in hypogonadal men following radical prostatectomy for prostate cancer, challenging the historical contraindication due to concerns about cancer recurrence. Several studies reviewed showed that TRT did not significantly increase prostate-specific antigen (PSA) levels or lead to biochemical recurrence, with

Read More »
June 26, 2025 No Comments

Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial

This randomized controlled trial compared radical prostatectomy (RP) with watchful waiting (WW) in 695 men with early prostate cancer over a median follow-up of 12 years, assessing symptom burden, androgen deprivation therapy (ADT) use, and quality of life (QoL). RP was associated with lower prostate cancer-specific mortality but higher rates

Read More »
June 26, 2025 No Comments